基本信息
浏览量:1
职业迁徙
个人简介
Dr. Markert is currently investigating cultured thymus tissue implantatoin in children with congenital athymia. Congenital athymia is a fatal disease as the patients have no T cells to defend against infection. There are several etiologies of congenital athymia including 22q11.2 deletion syndrome, CHARGE (coloboma, heart defects, choanal atresia, growth or mental retardation, genital abnormalities and ear anomalies and or deafness. Complete DiGeorge anomaly is a designation that encompasses the above in addition with patients with athymia who have heart and/or parathyroid defects. In research studies, patients with athymia who have no T cells are given postnatal cultured thymus tissue implants (CTTI). Of 95 patients with congenital athymia approximately 72% have developed T cells and survive. Dr. Markert is now studying patients previously given CTTI to learn how long the tissue functions and why the T cell numbers in her post thymus transplantation patients remain low for age - similar to the T cell numbers in patients with partial DiGeorge anomaly who do not need CTTI. In 2012, Dr. Markert began studies in an animal model to use CTTI to induce tolerance to solid organ transplants. This work in rats has been published and showed tolerance induction for solid organ transplants.
研究兴趣
论文共 65 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Elizabeth Daly Hicks,Noah O. Agada, Tyler R. Yates,Matthew S. Kelly,Jonathan S. Tam,Ronald M. Ferdman, Louis R. Dibernardo, John F. Madden,M. Anthony Moody,Mary Louise Markert
Frontiers in Immunology (2023): 1078976-1078976
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn